Michael S. Gordon - Publications, H-index & Citations

Michael S. Gordon

honorhealth research institute

72H指数

571论文数

2.8W被引数

收录论文 99

发表时间

Phase IB Trial of High Dose Ascorbic Acid + Nab-Paclitaxel + Cisplatin + Gemcitabine in Patients With Untreated Metastatic Pancreatic Cancer.I期B临床试验：高剂量抗坏血酸 + Nab-紫杉醇 + 顺铂 + 吉西他滨，用于未治疗的转移性胰腺癌患者。

Redox Biology

IF11.9

2025-10-25

OAAI

Gayle S. Jameson; S.Danielle LeGrand; Michael S. Gordon; Denise J. Roe; Betsy C. Wertheim; Kellen Olszewski; Josh Rabinowitz; Ron Evans; Michael Downes; Morgan Truitt; Ron Korn; Haiyong Han; Richard M. Miller; Michael T. Barrett; David Propper; Daniel D. Von Hoff; Erkut Borazanci

Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer 髓系靶向抗体PY159和PY314用于铂耐药性卵巢癌

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2025-03-13

OAAI

Yeku, Oladapo O.; Barve, Minal; Tan, Winston W.; Wang, Judy; Patnaik, Amita; Lorusso, Patricia; Richardson, Debra L.; Naqash, Abdul Rafeh; Lynam, Sarah K.; Fu, Siqing; Gordon, Michael; Hubbard, Joleen; Kummar, Shivaani; Kyriakopoulos, Christos; Dowlati, Afshin; Chamberlain, Marc; Winer, Ira

Phase II Trial of Vemurafenib plus Sorafenib in Advanced KRAS Mutated Pancreas Cancer

CANCER RESEARCH

IF16.6

2024-09-15

PREAI

Borazanci, Erkut; Jameson, Gayle; Khawaja, Muhammad; Cridebring, Derek; Shannon, Patricia; Gordon, Michael; Han, Haiyong; Moore, Jaeger; Von Hoff, Daniel; Posner, Richard; Hlavacek, William; Kolch, Walter; Kholodenko, Boris; Rukhlenko, Oleksii

Updated efficacy and safety of botensilimab plus balstilimab in patients with refractory metastatic sarcoma from an expanded phase I study 扩展性I期研究中，botensilimab联合balstilimab在难治性转移性肉瘤患者中的更新疗效与安全性。

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Wilky, B. A.; Trent, J. C.; Tsimberidou, A. M.; Gordon, M.; El-Khoueiry, A. B.; Bullock, A.; Henick, B. S.; Agulnik, M.; Mahadevan, D.; Singh, A.; Wu, W.; Avagyan, M.; Patel, J. M.; Grossman, J.; O'Day, S. J.; Schwartz, G.; Jones, R. L.

NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II study NKT2152，一种新型的口服HIF-2α抑制剂，在既往接受过治疗的晚期透明细胞肾癌（accRCC）患者（pts）中的初步结果：一项I/II期研究

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Jonasch, E.; McGregor, B. A.; Msaouel, P.; Logan, T.; Hall, E. T.; Bilen, M. A.; Falchook, G. S.; Shuch, B.; Zakharia, Y.; Hauke, R.; Gordon, M.; Naqash, A-R.; Ryan, C. W.; Srinivasan, R.; Xiao, J.; Sun, W.; Esguerra, M.; Lu, G.; Lager, J.; Choueiri, T. K.

Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial

NATURE MEDICINE

IF50

2024-06-13

OAAI

Bullock, Andrea J.; Schlechter, Benjamin L.; Fakih, Marwan G.; Tsimberidou, Apostolia M.; Grossman, Joseph E.; Gordon, Michael S.; Wilky, Breelyn A.; Pimentel, Agustin; Mahadevan, Daruka; Balmanoukian, Ani S.; Sanborn, Rachel E.; Schwartz, Gary K.; Abou-Alfa, Ghassan K.; Segal, Neil H.; Bockorny, Bruno; Moser, Justin C.; Sharma, Sunil; Patel, Jaymin M.; Wu, Wei; Chand, Dhan; Rosenthal, Katherine; Mednick, Gabriel; Delepine, Chloe; Curiel, Tyler J.; Stebbing, Justin; Lenz, Heinz-Josef; O'Day, Steven J.; El-Khoueiry, Anthony B.

Final outcomes analysis of the cell product SQZ-PBMC-HPV Phase 1 trial in incurable HPV16+solid tumors shows improved overall survival in patients with increased CD8+T cell tumor infiltration

MOLECULAR CARCINOGENESIS

IF3.2

2024-05-02

PREAI

Weaver, Alice N.; Iams, Wade T.; Park, Jong Chul; Mita, Monica; Holtick, Udo; Gordon, Michael S.; Rodabaugh, Kerry J.; Dhani, Neesha; Neupane, Prakash; Taylor, Matthew; Amanda Duvall, E.; Jennings, Julia; Miselis, Nathan R.; Loughhead, Scott; Warren, Marshelle S.; Bernstein, Howard; Klussmann, Jens P.; Baranda, Joaquina; Jimeno, Antonio

Evaluating the efficacy of personalized neoantigen cancer vaccine in preclinical model: A promising step towards precision immunotherapy

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

Halder, Tithi Ghosh; Gutowsky, Kate; Ng, Serina; Thode, Trason; Weston, Alexis; Kelley, Erin; Soria-Bustos, Jorge; Giron, Jorge A.; Bargenquast, Taylor; Kaadige, Mohan; Tripuraneni, Sanjana; Durbin, Brian; Rheinschmidt, Shelby; Adamson, Sydney; Gordon, Michael; Moser, Justin; Altin, John; Soldi, Raffaella; Sharma, Sunil

Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Wilky, B.; Trent, J. C.; Gordon, M.; El-Khoueiry, A. B.; Bullock, A.; Henick, B. S.; Schwartz, G. K.; Agulnik, M.; Mahadevan, D.; Patel, J.; Grossman, J.; Rosenthal, K.; O'Day, S. J.; Tsimberidou, A. M.

Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Marron, T. U.; Misleh, J. G.; Chen, C.; Wainberg, Z. A.; Powderly, J.; Boccia, R.; Gordon, M.; Segar, J.; Csiki, I.; Schanzer, J. M.; O'Toole, L.; Huang, N.; Seppa, J.; Glenn, J.; Klumpp, K.; Spira, A. I.

Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)

ANNALS OF ONCOLOGY

IF65.4

2023-06-01

OAAI

Bullock, A.; Fakih, M.; Gordon, M.; Tsimberidou, A.; El-Khoueiry, A.; Wilky, B.; Pimentel, A.; Margolin, K.; Mahadevan, D.; Balmanoukian, A.; Sanborn, R.; Schwartz, G.; Abou-Alfa, G.; Bockorny, B.; Moser, J.; Sharma, S.; Grossman, J.; Rosenthal, K.; O'Day, S.; Lenz, H.; Schlechter, B.

Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+patients with HPV16+solid tumors

INVESTIGATIONAL NEW DRUGS

IF2.7

2023-03-03

OAAI

Jimeno, Antonio; Baranda, Joaquina; Iams, Wade T.; Park, Jong Chul; Mita, Monica; Gordon, Michael S.; Taylor, Matthew; Dhani, Neesha; Leal, Alexis D.; Neupane, Prakash; Eng, Cathy; Yeku, Oladapo; Mita, Alain; Moser, Justin C.; Butler, Marcus; Loughhead, Scott M.; Jennings, Julia; Miselis, Nathan R.; Ji, Rui-Ru; Nair, Nitya; Kornacker, Martin; Zwirtes, Ricardo F.; Bernstein, Howard; Sharei, Armon

Phase 1 first-in-human study of dalutrafusp alfa, an anti-CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2023-02-06

OAAI

Tolcher, Anthony W.; Gordon, Michael; Mahoney, Kathleen M.; Seto, Anna; Zavodovskaya, Marianna; Hsueh, Chia-Hsiang; Zhai, Shuyan; Tarnowski, Thomas; Jurgensmeier, Juliane M.; Stinson, Susanna; Othman, Ahmed A.; Chen, Tianling; Strauss, James

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

CLINICAL CANCER RESEARCH

IF10.2

2022-06-13

OAAI

Kim, Tae Won; Burris, Howard A.; Luken, Maria J. de Miguel; Pishvaian, Michael J.; Bang, Yung-Jue; Gordon, Michael; Awada, Ahmad; Camidge, D. Ross; Hodi, F. Stephen; McArthur, Grant A.; Miller, Wilson H., Jr.; Cervantes, Andres; Chow, Laura Q.; Lesokhin, Alexander M.; Rutten, Annemie; Sznol, Mario; Rishipathak, Deepali; Chen, Shang-Chiung; Stefanich, Eric; Pourmohamad, Tony; Anderson, Maria; Kim, Jeong; Huseni, Mahrukh; Rhee, Ina; Siu, Lillian L.

Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer

ANNALS OF ONCOLOGY

IF65.4

2022-06-01

OAAI

Bullock, A.; Grossman, J.; Fakih, M.; Lenz, H.; Gordon, M.; Margolin, K.; Wilky, B.; Mahadevan, D.; Trent, J.; Bockorny, B.; Moser, J.; Balmanoukian, A.; Schlechter, B.; Feliu, W. Ortuzar; Rosenthal, K.; Bullock, B.; Stebbing, J.; Godwin, J.; O'Day, S.; Tsimberidou, A.; El-Khoueiry, A.

Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial

OPEN FORUM INFECTIOUS DISEASES

IF3.8

2022-05-11

OAAI

Winthrop, Kevin L.; Skolnick, Alan W.; Rafiq, Adnan M.; Beegle, Scott H.; Suszanski, Julian; Koehne, Guenther; Barnett-Griness, Ofra; Bibliowicz, Aida; Fathi, Reza; Anderson, Patricia; Raday, Gilead; Eagle, Gina; Ben-Yair, Vered Katz; Minkowitz, Harold S.; Levitt, Mark L.; Gordon, Michael S.

Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial

CLINICAL LUNG CANCER

IF3.3

2022-05-01

OAAI

Wong, Deborah J.; Bauer, Todd M.; Gordon, Michael S.; Bene-Tchaleu, Fabiola; Zhu, Jing; Zhang, Xiaosong; Cha, Edward

A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer

CANCER RESEARCH

IF16.6

2022-02-15

PREAI

Yap, Timothy A.; Basu, Cynthia; Goldman, Jonathan W.; Gordon, Michael; Hamilton, Erika; Kelly, Adrianne; Liu, Feng; Moreau, Allison R.; Neumann, Heather; Papadopoulos, Kyriakos; Rugo, Hope S.; Shapiro, Geoffrey I.; Vinayak, Shaveta; Zhou, Li; Jhaveri, Komal

SQZ-PBMC-HPV-101: Preliminary results of a first-in-human, dose-escalation study of a cell-based vaccine in HLA A*02+patients with recurrent, locally advanced, or metastatic HPV16+solid tumors

ANNALS OF ONCOLOGY

IF65.4

2021-12-01

OAAI

Park, J-C.; Baranda, J. C.; Mita, M. M.; Iams, W. T.; Gordon, M. S.; Taylor, M.; Dhani, N.; Loughhead, S. M.; Ji, R-R.; Zwirtes, R. F.; Kornacker, M.; Rosen, O.; Bernstein, H.; Jimeno, A.

Initial findings from an ongoing first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer

MOLECULAR CANCER THERAPEUTICS

IF5.5

2021-12-01

PREAI

Armstrong, Andrew J.; Gordon, Michael S.; Reimers, Melissa A.; Hussain, Arif; Patel, Vaibhav G.; Lam, Elaine T.; Sedkov, Alex; Potter, Von; Shore, Neal

研究方向